Damora Therapeutics (DMRA)
NASDAQ:DMRA
Want to see DMRA full AI Analyst Report?
Top Page
Damora Therapeutics
(NASDAQ:DMRA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$24.50
▼(-7.89% Downside)
Action:ReiteratedDate:04/08/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and continued cash burn), partially offset by a low-debt balance sheet. Technical indicators are mixed with subdued momentum, and valuation signals are limited due to the lack of meaningful P/E and no dividend yield. A positive leadership/board overhaul provides some incremental support but is not yet reflected in operating results.
Positive Factors
Low leverage / Financial flexibility
Very low debt and near-zero debt-to-equity materially reduce solvency risk and preserve optionality for a clinical-stage biotech. This durable financial flexibility supports continued R&D spending, allows for more favorable financing terms, and helps the company withstand trial timelines over the next several months.
Negative Factors
No revenue & widening losses
The company remains pre-commercial with no revenue and a sharp increase in net loss, reflecting high development spending and one-time items. Over a multi-month horizon this heavy loss profile drains resources, increases financing need, and heightens execution risk before any product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / Financial flexibility
Very low debt and near-zero debt-to-equity materially reduce solvency risk and preserve optionality for a clinical-stage biotech. This durable financial flexibility supports continued R&D spending, allows for more favorable financing terms, and helps the company withstand trial timelines over the next several months.
Read all positive factors
Damora Therapeutics (DMRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.44B
Dividend YieldN/A
Average Volume (3M)5.26M
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue GrowthN/A
EPS Growth75.41%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding60,303,210
10 Day Avg. Volume9,383,356
30 Day Avg. Volume5,257,093
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.12
Price to Sales (P/S)0.00
P/FCF Ratio-4.30
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-169.36K
Enterprise Value/Ebitda-5.88
Forecast
1Y Price Target
$43.20Price Target Upside62.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.32
Revenue Forecast (FY)N/A
Damora Therapeutics Business Overview & Revenue Model
Company Description
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also inv...
How the Company Makes Money
null...
Damora Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -181.00K | -830.00K | -490.00K | -441.00K |
| EBITDA | -210.84M | -16.72M | -35.63M | -60.72M | -51.79M |
| Net Income | -209.84M | -21.44M | -38.35M | -61.62M | -51.75M |
Balance Sheet | |||||
| Total Assets | 260.53M | 17.13M | 38.23M | 73.19M | 122.22M |
| Cash, Cash Equivalents and Short-Term Investments | 257.62M | 14.18M | 33.15M | 60.22M | 100.19M |
| Total Debt | 68.00K | 1.43M | 249.00K | 804.00K | 847.00K |
| Total Liabilities | 20.15M | 2.66M | 5.90M | 11.44M | 4.99M |
| Stockholders Equity | 240.38M | 14.47M | 32.33M | 61.75M | 117.22M |
Cash Flow | |||||
| Free Cash Flow | -6.73M | -18.62M | -36.91M | -43.13M | -52.53M |
| Operating Cash Flow | -6.73M | -18.62M | -36.91M | -42.93M | -52.31M |
| Investing Cash Flow | -17.37M | 11.65M | 22.33M | 12.38M | -48.05M |
| Financing Cash Flow | 266.84M | 0.00 | 2.88M | 507.00K | 0.00 |
Damora Therapeutics Technical Analysis
Positive
26.60
Price Trends
26.36
Positive
25.55
Positive
16.02
Positive
Market Momentum
0.28
Negative
53.72
Neutral
65.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DMRA, the sentiment is Positive. The current price of 26.6 is above the 20-day moving average (MA) of 25.10, above the 50-day MA of 26.36, and above the 200-day MA of 16.02, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 53.72 is Neutral, neither overbought nor oversold. The STOCH value of 65.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DMRA.
Damora Therapeutics Risk Analysis
Damora Therapeutics disclosed 88 risk factors in its most recent earnings report. Damora Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Damora Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.44B | -0.04 | -134.39% | ― | ― | 75.41% | |
47 Neutral | $8.89M | ― | -334.42% | ― | ― | -464.26% | |
43 Neutral | $3.22M | -0.15 | -381.74% | ― | ― | 95.78% | |
42 Neutral | $3.93M | -0.42 | -157.24% | ― | ― | 58.93% |
* Healthcare Sector Average
DMRA
Damora Therapeutics
23.93
21.13
754.64%
MTNB
Matinas BioPharma
0.61
0.02
3.90%
QNRX
Quoin Pharmaceuticals
5.93
-0.84
-12.41%
SILO
Silo Pharma
0.45
-0.30
-40.13%
GRI
GRI Bio
2.23
-48.73
-95.62%
CDT
CDT Equity
2.25
-1,671.75
-99.87%
Damora Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Damora Therapeutics Announces Major Leadership and Board Overhaul
Positive
Mar 23, 2026
On March 23, 2026, Damora Therapeutics announced a sweeping leadership overhaul, appointing industry veteran Jennifer Jarrett as president and chief executive officer effective March 30, 2026, and adding her to the board as a Class II director. Ja...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.